FBXO22

Across TCGA pan-cancer cohorts, FBXO22 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FBXO22 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FBXO22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO22 expression acts as an unfavorable survival marker.

LUSC, ACC, and BLCA are the cancer types where FBXO22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.190	0.750	<.001	16	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
BLCA	OS	Median	III,IV	0.149	0.581	.020	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FBXO22–LUSC (OS)

Open the LUSC breakdown →